Abstract
A new combinatorial approach harnesses the power of immuno- and virotherapy in a vesicular stomatitis virus (VSV) vector carrying a cDNA library that expresses normal human prostate antigens, thus providing proof of principle that this vaccine can induce prostate tumor rejection in mice (pages 854–859). This strategy might bypass many of the issues associated with conventional cancer immuno- or virotherapy.
MeSH terms
-
Animals
-
Antigens, Neoplasm / genetics
-
Antigens, Neoplasm / immunology
-
Antigens, Neoplasm / therapeutic use*
-
Cancer Vaccines / genetics
-
Cancer Vaccines / immunology
-
Cancer Vaccines / therapeutic use*
-
DNA, Complementary / genetics
-
Genetic Vectors / genetics
-
Genetic Vectors / immunology
-
Humans
-
Immunotherapy / methods
-
Male
-
Mice
-
Prostatic Neoplasms / immunology
-
Prostatic Neoplasms / therapy*
-
Vesiculovirus / genetics
-
Vesiculovirus / immunology
Substances
-
Antigens, Neoplasm
-
Cancer Vaccines
-
DNA, Complementary